Sex difference in the expression of PD-1 of non-small cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sex difference in the expression of PD-1 of non-small cell lung cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-20
DOI
10.3389/fimmu.2022.1026214
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- Testosterone deficiency in men receiving immunotherapy for malignant melanoma
- (2021) Madeline Peters et al. Oncotarget
- Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer
- (2020) Chong Shuai et al. Frontiers in Oncology
- Estrogen: The necessary evil for human health, and ways to tame it
- (2018) Seema Patel et al. BIOMEDICINE & PHARMACOTHERAPY
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Androgen-dependent immune modulation in parasitic infection
- (2018) Julie Sellau et al. Seminars in Immunopathology
- The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer
- (2017) Haitao Ma et al. IMMUNOLOGICAL INVESTIGATIONS
- Estrogen, Estrogen Receptor and Lung Cancer
- (2017) Li-Han Hsu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
- (2016) Steffen Filskov Sorensen et al. LUNG CANCER
- Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion
- (2016) Xue Pan et al. Experimental and Therapeutic Medicine
- Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay
- (2015) Yan G. Ni et al. AAPS Journal
- Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
- (2013) SR Greisen et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Child Mortality Estimation: Estimating Sex Differences in Childhood Mortality since the 1970s
- (2012) Cheryl Chriss Sawyer PLOS MEDICINE
- Sex Disparities in Cancer Mortality and Survival
- (2011) M. B. Cook et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- PD-1, gender, and autoimmunity
- (2010) Ravi K. Dinesh et al. AUTOIMMUNITY REVIEWS
- B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses
- (2010) P.-Y. Lin et al. JOURNAL OF IMMUNOLOGY
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Membrane Estrogen Receptor Regulates Experimental Autoimmune Encephalomyelitis through Up-regulation of Programmed Death 1
- (2009) C. Wang et al. JOURNAL OF IMMUNOLOGY
- A review of novel biological tools used in screening for the early detection of lung cancer
- (2009) R Ghosal et al. POSTGRADUATE MEDICAL JOURNAL
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1
- (2008) Chunhe Wang et al. IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started